Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

NCT04741074 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped low recruitment

Conditions

CKD
Diabetic Kidney Disease
Type 2 Diabetes Mellitus in Obese
Obesity
Severe Obesity

Interventions

DRUG: Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
DRUG: Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution

Sponsor

Geisinger Clinic